Equities

Sunho Biologics Inc

Sunho Biologics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)5.75
  • Today's Change-0.150 / -2.54%
  • Shares traded15.60k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 08:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sunho Biologics Inc is a company mainly engaged in the research, development and production of biotechnology. The Company is primarily engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The Company has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.

  • Revenue in HKD (TTM)--
  • Net income in HKD-118.07m
  • Incorporated2021
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
JW (Cayman) Therapeutics Co Ltd190.31m-690.94m514.81m323.00--0.3136--2.71-1.68-1.680.46143.950.07471.8711.48478,163.50-27.11-39.77-31.71-44.0050.40---363.06-1,316.812.76--0.2043--19.32--9.23---19.87--
Brii Biosciences Ltd0.00-292.12m679.38m95.00--0.2157-----0.4003-0.40030.004.310.00----0.00-8.89---9.01--------------0.007---98.80--63.90------
Genor Biopharma Holdings Ltd15.92m-578.31m857.97m28.00--0.7257--53.88-1.14-1.140.03132.270.00930.01780.2277153,116.50-33.87-55.46-39.06-63.7397.5966.56-3,638.27-14,819.185.73--0.003---100.00--7.65---48.85--
Sunho Biologics Inc-100.00bn-118.07m924.33m----1.53-----0.8765-0.8765--3.85------------------------14.77-4,626.670.0516-------155.25------
Wuhan YZY Biopharma Co Ltd0.00-201.97m1.20bn114.00--21.92-----1.06-1.060.000.28150.00----0.00-83.99---230.17----------1.21-44.350.7078-------1.50------
Frontage Holdings Corp2.03bn47.53m1.24bn1.66k26.530.47353.670.6130.0230.0230.98921.290.470156.234.181,151,748.001.064.461.305.2828.5634.002.269.921.252.190.3110.003.7925.61-58.00-0.782640.43--
Hua Medicine119.89m-289.85m1.26bn172.00------10.48-0.2957-0.29570.1223-0.03720.07791.511.90677,343.20-18.84-25.61-23.63-28.8137.72---241.76-1,654.704.64--1.14--335.31---3.80--14.07--
Mabpharm Ltd166.86m-227.72m1.26bn347.00--9.92--7.54-0.0552-0.05520.04050.03070.1640.19373.26480,867.20-22.38-21.42-31.11-27.4986.91---136.47-486.400.6836-23.090.679--55.87--0.694---26.85--
Jacobio Pharmaceuticals Group Co Ltd25.51m-398.26m1.38bn298.00--1.39--54.14-0.513-0.5130.03291.260.016--2.4184,767.09-24.89-45.76-28.66-49.303.45---1,560.88-372.22----0.1794---33.66--3.43--19.18--
Immunotech Biopharm Ltd0.00-340.29m1.38bn211.00--15.51-----0.6613-0.66130.000.17340.00----0.00-35.21-37.42-55.75-45.48--------0.3638-2.440.6119-------5.25---8.46--
Data as of Sep 20 2024. Currency figures normalised to Sunho Biologics Inc's reporting currency: Hong Kong Dollar HKD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.